Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Day (May 2023)
11 slides from Orion Oyj Class A's investor day presentation, May 25, 2023
Slide 1: Branded Products Business Division
Branded Products Business Division Hao Pan, Senior Vice President
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Overview of Branded Products Business Division
Overview of Branded Products Business Division 300 278 250 -19% EUR million 200 Q1'22 Legacy 150 Targeted Q1'23 products Maximised 100 73 customer 60 2022 with brand value 50 engagement value 0 Net sales Sales split in Q1'23 Build on the current portfolio in Europe and Asia-Pacific 1% 8% 54% Easyhal
Slide 4: Building blocks for growth – Branded Products
Building blocks for growth – Branded Products Maximise the value of Build on the current How the current product product portfolio portfolio Easyhaler® Respiratory Internal R&D Parkinson’s disease Amneal collaboration Entacapone1 Other CNS3 In-licensing HRT2 range Women’s Health Geographic expansion
Slide 5: Orion as a leading company in Parkinson's Disease
Orion as a leading company in Parkinson’s Disease 1 300 267 Orion-developed generic levodopa- carbidopa product in a launch EUR million 200 Entacapone remains an 113 important product for phase in Europe 100 Orion even 10 years after loss of exclusivity Parkinson’s Disease (PD) products 2 0 Orion's
Slide 6: Easyhaler continues to be a great story for Orion
Easyhaler®continues to be a great story for Orion AVERAGE EMISSION PER INHALER S I M P LE D E V I C E T O U S E , FURTHER REDUCED FROM 0.58KG (2020) ACTIVATED BY INHALATION TO 0.55KG (2023) >100 million devices INNOVATIVE IN-HOUSE 6 I N HA L A T I O N P R O D U C T S U S I N G INHALATION PLATFORM de
Slide 7: Green transition increases demand for DPIs…
Green transition increases demand for DPIs… Green transition – probably the Healthcare systems are doing their …and guiding to use DPIs like greatest megatrend impacting our bit – initiatives to reduce the use of Easyhaler® (dry-powder inhalers) generation MDIs (metered-dose inhalers)… • Global Init
Slide 8: …and creates growth opportunities for Easyhaler
…and creates growth opportunities for Easyhaler® • Easyhaler® is a dry-powder inhaler (DPI) • A broad portfolio of products particularly in segments, which are dominated by MDIs and where there are limited alternative DPIs available • Increased demand for mono products (ie. with one active pharmaceu
Slide 9: Key success factors
Key success factors Implementation of Take care of green initiatives in supply chains Europe Ensure portfolio Production expansion through efficiency in-licensing and R&D Adapt to possible Managing changes in pricing pressure regulation 9 CMD 25 May 2023 © Orion Corporation
Slide 10: Key takeaways
Key takeaways 1. Green transition creates further growth opportunities for Easyhaler® 2. Orion remains a leading company in Parkinson’s Disease 3. Current portfolio a good platform to build on new business in respiratory, Parkinson’s Disease, other CNS and Women’s Health 10 CMD 25 May 2023 © Orion C
Slide 11: CMD 25 May 2023 © Orion Corporation
11 CMD 25 May 2023 © Orion Corporation